Article

Lid hygiene kit designed for management of lid margin diseases

The Cliradex Complete Advanced Lid Hygiene Kit is a new product that may help manage symptoms of lid margin diseases. The kit’s Cliradex Advance Care gel-whose main component is 4-Terpineol-has a miticidal effect and cleansing properties that can help improve ocular health.

 

Take-home:

The Cliradex Complete Advanced Lid Hygiene Kit is a new product that may help manage symptoms of lid margin diseases. The kit’s Cliradex Advance Care gel-whose main component is 4-Terpineol-has a miticidal effect and cleansing properties that can help improve ocular health.

 

 

By Nancy Groves; Reviewed by Preeya K. Gupta, MD

Durham, NC-A new lid hygiene kit for lid margin and ocular surface diseases helps manage the symptoms of conditions, such as blepharitis, demodex, meibomian gland dysfunction, rosacea, and dry eye diseases.

The comprehensive lid hygiene protocol (Cliradex Complete Advanced Lid Hygiene Kit, Bio-Tissue) includes a formulation gel with a stronger concentration of 4-Terpineol than the original Cliradex product, intended for application in the office by a doctor or trained technician. The gel is well tolerated and effective, said Preeya K. Gupta, MD, assistant professor of ophthalmology, Duke Eye Center, Duke University, Durham, NC.

More in this issue:  IOL system a novel surgical treatment for dry AMD

She has been using the kit since it was released in early fall and has observed that in-office application of the gel and home use of the lid wipes helps reduce inflammation, crusting, and redness along patients’ eyelids.

“Demodex blepharitis is a common condition that is often overlooked,” Dr. Gupta said. “When left untreated it can create ocular surface inflammation, chronic eyelid crusting and redness, as well as ocular irritation.

“Demodex infestation can be hard to eradicate and has been linked to rosacea,” she said. “Tea tree oil has shown to be effective in a dose-dependent fashion; however, in high concentrations can be quite difficult to tolerate.

Like other Cliradex products, the gel isolates 4-Terpineol-the most active component in tea tree oil-to help manage the symptoms of moderate to severe lid margin disease. Other ingredients help with removal of lid margin debris and makeup.

 

Using the kit’s dual-sided applicator, the physician or technician brushes the gel into the patient’s lids and lashes to clean them. After treatment, the kit’s carton of lid wipes is sent home with the patient to be used once or twice a day as part of the ocular hygiene protocol.

“In the past, we’ve asked people to use tea tree oil shampoo to scrub the lashes, and most of them described intense stinging and discomfort, but this (Cliradex) has been a well tolerated treatment,” Dr. Gupta said.

One reason for this may be that the formulation of 4-Terpineol eliminates application of other tea tree oil components that may cause patient intolerance. Dr. Gupta explained that when patients use tea tree oil shampoo or mix their own with a combination tea tree oil and baby shampoo, the concentration of active ingredients can vary significantly with unpredictable results. 4-Terpineol has a greater miticidal effect than tea tree oil itself and has a lower risk of toxicity or allergic reactions when used as a topical formulation, according to Bio-Tissue.

 

Preeya K. Gupta, MD

E: preeya.gupta@duke.edu

Dr. Gupta is a consultant for Bio-Tissue.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.